Life Science Compliance Update

February 28, 2017

Qordata Hosting Compliance Insights Webinar March 1


On Wednesday, March 1, 2017, qordata is hosting a webinar, titled, “Making Analytics Work at Merck USA.” The webinar features Wendy Derosa, Associate Director, Data Analytics and Transparency at Merck USA and Bryan Timer, Associate Director, Data Analytics & Transparency at Merck USA.

The journey between understanding the compliance requirements behind CMS Submission, and integrating that with Merck’s internal systems resulted in a successful intersection of technology, legal and sales. Attendees of this webinar will learn how Ms. Derosa and Mr. Timer took a global challenge and turned it into a success story for Merck USA and its counterparts across the world.

Agenda of Webinar

This webinar will take a high-level approach to Compliance. The presenter will share her own experiences in joining this role as the Sunshine Act was being introduced in USA. Attendees will benefit from learning how a global organization such as Merck was able to combine resources from technology, operations, sales and legal to roll out a precise and multi-channel reporting solution.

The webinar will be conducted as an exchange of questions and answers between both Merck representatives and Mohammad Ovais, Founder and CEO of qordata. Responses may be as detailed as possible, and will include input from slides. The total duration per question is framed within 5 minutes, so that the topic may be covered holistically and in-depth.

The agenda will focus on the following topics:

  • Challenges of introducing an internal compliance reporting mechanism in a multi-market organization like Merck
  • Integrating technology with sales, operations and compliances for timely identification and redress of data errors
  • Transition from basic internal reporting to a culture of advanced spend analytics
  • Tools and resources for enhancing compliance program

Expected Takeaways from the Webinar

With speakers like Ms. Derosa and Mr. Timer, attendees can expect to:

  • Acquire insights into how technology integrated with sales, compliance and operations can assist in timely identification of data errors
  • Learn about tools and resources that assist in formulating sophisticated compliance programs
  • Acquire detailed information about how data analytics helped Merck USA with its compliance efforts

If you are a decision maker responsible for designing and executing internal compliance structures within the realm of the global Compliance, Technology, Internal Audit and Marketing C-Suite, you are highly encouraged to attend. Life Sciences Industry participants seeking solutions to program challenges will benefit from the compliance-analytics experience at Merck USA.

If you are interested in attending this webinar, you can register for free here.

October 18, 2016

Omnicare Inc. to Pay Over $28 Million to Settle Kickback Allegations


As announced on Monday, October 17, 2016, by the United States Department of Justice (“DOJ”), the nation’s largest nursing home pharmacy, Omnicare Inc. (a CVS Health company), has agreed to pay $28.125 million to resolve allegations that it solicited and received kickbacks from pharmaceutical manufacturer Abbott Laboratories in exchange for promoting Depakote for nursing home patients.

According to the government’s complaint, Omnicare disguised the kickbacks it received from Abbott in a variety of ways. Abbott allegedly made payments to Omnicare under the guise of “grants” and “educational funding,” even though their true purpose was to induce Omnicare to recommend Depakote. The complaint provided an example revolving around its “Re*View” program in which Abbott funded with a $50,000 grant. While Omnicare claimed that Re*View was a “health management” and “educational” program, the complaint alleges that it was simply a means by which Omnicare solicited kickbacks from pharmaceutical manufacturers in exchange for increasing the utilization of their drugs on elderly nursing home residents. In internal documents, Omnicare allegedly referred to Re*View as its “one extra script per patient” program.  

The complaint also alleged that Omnicare entered into agreements with Abbott by which Omnicare was entitled to increasing levels of rebates from Abbott based on the number of nursing home residents serviced, and the amount of Depakote prescribed per resident. Abbott allegedly funded Omnicare management meetings on Amelia Island in Florida, offered free tickets to sporting events to Omnicare management, and made other payments to local Omnicare pharmacies.

Of the settlement amount, approximately $20.3 million will go to the United States, with $7.8 million allocated to cover Medicaid program claims by states that elect to participate in the settlement.

Benjamin C. Mizer, Principal Deputy Assistant Attorney General and head of the DOJ Civil Division, stated,

Every day, elderly nursing home residents suffering from dementia rely on the independent judgment of our nation’s healthcare professionals for their personal care and their medical treatment. Kickbacks to entities making drug recommendations compromise their independence and undermine their role in protecting nursing home residents from the use of unnecessary drugs.

Special Agent in Charge Nicholas DiGiulio of the Department of Health and Human Services Office of Inspector General (HHS OIG), said, “it is disturbing that any health care corporation would pay kickbacks that corrupt the professional medical decision making process in order to pad their profits. These practices are unacceptable and will not be tolerated.”

This settlement, together with prior settlements with Abbott and PharMerica, resolves allegations in two federal court lawsuits pending in the Western District of Virginia, filed by Richard Spetter and Meredith McCoyd, former Abbott employees. The United States filed a complaint-in-intervention against Omnicare in December 2014 and as part of today’s resolution, McCoyd will receive $3 million from the federal share of the settlement.

Omnicare is a Repeat Offender

2012 Settlement

This is not Omnicare’s first settlement with the DOJ. In 2012, the company agreed to pay $124.24 million for allegedly offering improper financial incentives to skilled nursing facilities in exchange for their continued selection of Omnicare drugs to elderly Medicare and Medicaid beneficiaries.

That settlement resolved allegations that Omnicare submitted false claims by entering into below-cost contracts to supply prescription medication, and other pharmaceutical drugs, to skilled nursing facilities (Medicare and Medicaid participants) and their patients, to induce the facilities to use Omnicare as their pharmacy provider. In addition to the facilities’ claims for reimbursement from Medicare for short-term rehabilitation treatment rendered to patients, Omnicare submitted additional claims for reimbursement to Medicare and Medicaid for drugs Omnicare supplied.

This settlement resolved allegations, also brought in two lawsuits, that Omnicare violated the Anti-Kickback Statute. The first whistleblower, former Omnicare employee Donald Gale, will receive $17.24 million. Of the $124.24 million settlement, states received $8.24 million.

2009 Settlement

In November 2009, Omnicare settled a case for $98 million that alleged that the pharmacy committed Medicaid fraud through several kickback schemes, including a whistleblower allegation that pharmaceutical manufacturer Johnson & Johnson paid Omnicare to increase sales of J&J’s Risperdal anti-psychotic drug.

Bernard Lisitza, a former Omnicare employee, alleged that J&J made quarterly rebate payments on Omnicare’s purchases of Risperdal under rebate agreements both entities executed in April 1997 and March 2000. The agreements allegedly conditioned rebate payment upon Omnicare’s engaging in an “active intervention program” to convince physicians to prescribe Risperdal and requiring that all competitive anti-psychotic products be “Prior Authorized for Risperdal failure.”

2006 Settlement

In November 2006, Omnicare paid $49.5 million to settle Medicaid fraud charges that it switched the drugs of senior citizens in nursing homes and other facilities, in an attempt to evade Medicaid price ceilings. These charges primarily involved generic forms of Zantac and Prozac.


This case is part of a much larger investigation on the use of medications in nursing homes.  Omnicare’s history shows that for more than a decade, the company has engaged in a variety of questionable kickback schemes to gain an edge over its competitors, in addition to other growth strategies that the federal government has intervened to stop. It is interesting to note that most, if not all, of these cases were initially brought by whistleblowers.  The media around this case was a simple rehashing by the government from when DOJ first filed the complaint in 2014 and the actions are all pre 2008 activities.

Omnicare has been referred to as the “King of Kickbacks,” as it is “one of the top violators of federal laws designed to protect the integrity and viability of Medicare, Medicaid, and other taxpayer-funded government health care programs.”  

It is likely that Omnicare has taken steps to improve their compliance programs and monitor them for effectiveness. Or, alternatively, maybe now that Omnicare has been acquired by CVS Health as of 2015, more checks and balances have been put in place.


Complaint 2014

DOJ Press Release Settlement 10-17-2016

September 30, 2016

Webinar: Open Payments Retrospect and Looking Forward


On October 13, 2016, qordata will be hosting a webinar, “Retrospect and Looking Forward: A Review of Two Full Years of Open Payments Data and Media Coverage, The Indications for the Future.”

With three years of published public data available through CMS submissions in Open Payments, the media is working hard at mining transparency data to bring health care fraud cases to the enforcement authorities’ attention. As time passes by, the government is also enhancing the ways in which it prosecutes, arrests and penalizes those engaged in fraud. With the media working hard to bring these cases to light, pharma companies need to work more efficiently in terms of documenting their spend data.

Presenting the webinar will be our very own Thomas Sullivan, along with Zafar Ahmed of qordata. The webinar will go through the 2014-2015 Open Payments data, discuss the media on Open Payments during the week of the 2015 release, evaluate prosecutions using Open Payments, deliberate the CMS questions on Open Payments, assess Congressional actions on Open Payments, and review global ag spend and media.

In this webinar, Thomas Sullivan will give a detailed review of the 2014-2015 Open Payments Data, evaluate persecutions and provide an in-depth assessment of the congressional actions on Open Payments.  He will further provide information about the ways in which Open Payments data and other tied in spend reports are being evaluated by the media in hopes of finding data anomalies.

Chief Compliance Officers, Directors of Compliance, Managers of Compliance, and any other interested parties are encouraged to attend and register here.


Preview | Powered by FeedBlitz


March 2017
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31